“Whoa! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer

<h5>Background</h5> Evidence to support the use of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin chemotherapy regimens in people with advanced non-small-cell lung cancer is limited.</P><h5>Objective</h5> To determine if gefitinib, in combination with paclitaxel and carboplatin chemotherapy improves survival outcomes in people with advanced non-small-cell lung cancer.</P><h5>Setting</h5> This multicentre study was conducted mainly (80%) in the United States.</P><h5>Method</h5> Multicentre randomised controlled trial.</P><h5>Participants</h5> 1037 people (∼60% male, median age ∼61 years, range 26–86 years) with histologically confirmed non-small-cell lung cancer (NSCLC) and disease stage IIIa ( n = 30, 3%); IIIb without malignant pleural effusion ( n = 41, 4%); IIIb with malignant pleural effusion ( n = 127, 12%) or stage IV ( n = 834, 80%; note: information not available from all participants) with a WHO performance status of 0 ( n = 367, 35%), 1 ( n = 554, 53%) or 2 ( n = 114, 11%). People were excluded if they: had mixed NSCLC plus small-cell lung cancer; had previously received chemotherapy; had brain metastases that were newly diagnosed or had not been treated with surgery or radiation; had previously been treated for CNS metastases or spinal-cord compression http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Treatment Reviews Elsevier
Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.